Columns & Departments
Verdicts
Due to a med mal verdict, an ex-prisoner's estate receives $1.75 million .
Features
Top 10 Equipment Acquisition Trends for 2016
The Equipment Leasing and Finance Association (ELFA) has released its list of Top 10 Equipment Acquisition Trends for 2016.
Features
When FCPA Charges Break the Mold
Normally, when a violation of the FCPA comes to mind, it looks a lot like this: A company, due to either corrupt intent or maybe just poor compliance practices, pays off a foreign official in return for some sort of business benefit. It's true that this is often how FCPA cases come to be, but not always.
Columns & Departments
Business Crimes Hotline
Discussion of a late-year wave of hospital FCA settlements.
Facebook's $20 Million Privacy Settlement Clears Appeals Court
The U.S. Court of Appeals for the Ninth Circuit on Jan. 6 upheld a $20 million class action settlement that resolved privacy claims against Facebook Inc. over a feature that posted users names and images along with advertising promotions.
Columns & Departments
Case Notes
Analysis of a GM trial in which "Similar Incident" evidence was permitted.
How California's Title 24 Can Impact Leases
The most significant effects that California Code of Regulations Title 24 has on a lease relates to which party will bear the cost of the upgrades required to make the space compliant with the legislation. Here's what you need to know.
Features
'Obstetric Violence' and Modern American Medical Jurisprudence
A recent Yahoo! Parenting article grouped a particular lawsuit under the larger rubric of "obstetric violence." But, what is "obstetric violence" and how does it fit into the modern American medical jurisprudence?
Features
Off-Label Promotion and Product Liability
The pharmaceutical industry has recently felt empowered and emboldened by one final court decision and another pending case that would seemingly allow companies to distribute, proactively, information about unapproved uses, i.e. , off-label, so long as the information is truthful and not misleading. However, companies must, nevertheless, consider potential product liability ramifications. There is no indication that, because firms may now be allowed certain latitude in one area, they are immune from product liability exposure.
Columns & Departments
Court Watch
Court Dismisses Franchise Act Claims <br>Court Grants Franchisor's Motion to Compel Arbitration
Need Help?
- Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
- Need other assistance? email Customer Service or call 1-877-256-2472.
MOST POPULAR STORIES
- The DOJ's New Parameters for Evaluating Corporate Compliance ProgramsThe parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.Read More ›
- Use of Deferred Prosecution Agreements In White Collar InvestigationsThis article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.Read More ›
- The DOJ's Corporate Enforcement Policy: One Year LaterThe DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.Read More ›
- Strategy vs. Tactics: Two Sides of a Difficult CoinWith each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.Read More ›
- Defending Your Career: Self Advocacy at Review TimeFirms have taken a hit due to COVID-19 and some will use this review cycle to pinpoint underperformers and reduce compensation. This is why it's even more important for you to make a case for yourself.Read More ›
